[The profile of severe asthmatics: Results from a specialized asthma clinic].

IF 0.7 Q4 RESPIRATORY SYSTEM
Zeynep Çelebi Sözener, Betül Özdel Öztürk, Ömür Aydın, Dilşad Mungan, Sevim Bavbek
{"title":"[The profile of severe asthmatics: Results from a specialized asthma clinic].","authors":"Zeynep Çelebi Sözener, Betül Özdel Öztürk, Ömür Aydın, Dilşad Mungan, Sevim Bavbek","doi":"10.5578/tt.20239919","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In patients with severe asthma, individualized treatment, and appropriate phenotyping are required to achieve control. In our study, our aim was to examine the characteristics of a specific patient group in a specialized tertiary asthma outpatient clinic, which is the primary setting for evaluating severe asthma patients, with the intention of obtaining national data.</p><p><strong>Materials and methods: </strong>In this cross-sectional observational study, sociodemographic, clinical presentations, laboratory results, and spirometry measurements of patients with severe asthma who were followed up in our specialized asthma outpatient clinic for at least one year were recorded. Patients were defined as eosinophilic if they had a blood eosinophil count of 300/µL or higher at least twice during the oral corticosteroid free-period or 150/µL or higher under oral corticosteroids as allergic if they had sensitization to at least one inhalant allergen consistent with their history.</p><p><strong>Result: </strong>Overall, 201 severe asthma patients (74.1% female) with a median disease duration of 15 (min-max= 1-49) years and a median follow-up duration of 7 (min-max= 1-40) years were analyzed. Most of the patients (56.7%) had adult-onset asthma [median age of onset was 32 (min-max= 10-62) years]. Overweight and obese patients were in the majority (31.8%, and 41.8%, respectively) and the median body mass index was 29 (min-max= 17.5-49.5). More than half of the patients (55.2%) had controlled asthma and the median Asthma Control Test score at the last visit was 23. Biologic therapies were applied to 73.1% (n= 147) of the patients [60.5% (n= 89) omalizumab, 39.5% (n= 58) mepolizumab]. Half of the group was allergic (49.3%) and three-quarters of them were eosinophilic (72.1%). Allergic patients had earlier asthma onset and had more controlled disease than nonallergic ones. Eosinophilic patients were younger and less obese than noneosinophilic patients. Obese and late-onset asthmatics had more uncontrolled disease than normal weight subjects and early onset patients.</p><p><strong>Conclusions: </strong>The high rate of disease control in the patients with severe asthma in the current study demonstrated the importance of targeted individualized therapy with accurate phenotyping in specialized asthma outpatient clinics.</p>","PeriodicalId":45521,"journal":{"name":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795275/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5578/tt.20239919","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: In patients with severe asthma, individualized treatment, and appropriate phenotyping are required to achieve control. In our study, our aim was to examine the characteristics of a specific patient group in a specialized tertiary asthma outpatient clinic, which is the primary setting for evaluating severe asthma patients, with the intention of obtaining national data.

Materials and methods: In this cross-sectional observational study, sociodemographic, clinical presentations, laboratory results, and spirometry measurements of patients with severe asthma who were followed up in our specialized asthma outpatient clinic for at least one year were recorded. Patients were defined as eosinophilic if they had a blood eosinophil count of 300/µL or higher at least twice during the oral corticosteroid free-period or 150/µL or higher under oral corticosteroids as allergic if they had sensitization to at least one inhalant allergen consistent with their history.

Result: Overall, 201 severe asthma patients (74.1% female) with a median disease duration of 15 (min-max= 1-49) years and a median follow-up duration of 7 (min-max= 1-40) years were analyzed. Most of the patients (56.7%) had adult-onset asthma [median age of onset was 32 (min-max= 10-62) years]. Overweight and obese patients were in the majority (31.8%, and 41.8%, respectively) and the median body mass index was 29 (min-max= 17.5-49.5). More than half of the patients (55.2%) had controlled asthma and the median Asthma Control Test score at the last visit was 23. Biologic therapies were applied to 73.1% (n= 147) of the patients [60.5% (n= 89) omalizumab, 39.5% (n= 58) mepolizumab]. Half of the group was allergic (49.3%) and three-quarters of them were eosinophilic (72.1%). Allergic patients had earlier asthma onset and had more controlled disease than nonallergic ones. Eosinophilic patients were younger and less obese than noneosinophilic patients. Obese and late-onset asthmatics had more uncontrolled disease than normal weight subjects and early onset patients.

Conclusions: The high rate of disease control in the patients with severe asthma in the current study demonstrated the importance of targeted individualized therapy with accurate phenotyping in specialized asthma outpatient clinics.

[严重哮喘患者的概况:哮喘专科门诊的结果]。
简介:对于重症哮喘患者来说,需要进行个体化治疗和适当的表型分析,以达到控制病情的目的。在我们的研究中,我们的目标是在一家专门的三级哮喘门诊中研究特定患者群体的特征,该门诊是评估重症哮喘患者的主要场所,目的是获得全国性数据:在这项横断面观察研究中,我们记录了在哮喘专科门诊随访至少一年的重症哮喘患者的社会人口学、临床表现、实验室结果和肺活量测量结果。如果患者在无口服皮质类固醇期间至少两次血液中嗜酸性粒细胞计数达到或超过 300 个/μL,或在口服皮质类固醇期间达到或超过 150 个/μL,则被定义为嗜酸性粒细胞患者;如果患者对至少一种与病史相符的吸入性过敏原过敏,则被定义为过敏性患者:总共分析了 201 名重症哮喘患者(74.1% 为女性),中位病程为 15 年(最小-最大= 1-49),中位随访时间为 7 年(最小-最大= 1-40)。大多数患者(56.7%)为成人发病型哮喘[发病年龄中位数为 32 岁(最小-最大= 10-62 岁)]。超重和肥胖患者占大多数(分别为 31.8% 和 41.8%),体重指数中位数为 29(最小-最大= 17.5-49.5)。超过一半的患者(55.2%)哮喘得到了控制,最后一次就诊时哮喘控制测试的中位数为 23 分。73.1%的患者(人数= 147)使用了生物疗法[60.5%(人数= 89)奥马珠单抗,39.5%(人数= 58)美博利珠单抗]。这组患者中有一半是过敏性患者(49.3%),四分之三是嗜酸性粒细胞患者(72.1%)。与非过敏性患者相比,过敏性患者的哮喘发病时间更早,病情控制得更好。嗜酸性粒细胞患者比非嗜酸性粒细胞患者更年轻,肥胖程度更轻。与体重正常者和发病较早的患者相比,肥胖和发病较晚的哮喘患者未得到控制的疾病较多:本次研究中,重症哮喘患者的病情控制率很高,这说明了在哮喘专科门诊中通过准确的表型分析进行有针对性的个体化治疗的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.50
自引率
9.10%
发文量
43
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信